Pulse Biosciences Initiates Patient Enrollment in Pivotal NANOPULSE-AF Study

Key Facts

1Pulse Biosciences has commenced patient enrollment in its NANOPULSE-AF pivotal study.

2The study aims to evaluate the company's proprietary NPS technology for the treatment of atrial fibrillation (AF).

Pulse Biosciences (PLSE) has officially commenced patient enrollment in its pivotal NANOPULSE-AF clinical trial. The study is designed to evaluate the safety and efficacy of the company's proprietary Nano-Pulse Stimulation (NPS) technology. This innovative treatment targets atrial fibrillation (AF), a significant and growing market within the cardiac care sector. This milestone represents a critical step for the company as it seeks regulatory approval and prepares for potential commercialization. Successfully advancing this trial is seen as a major move toward entering the large-scale cardiac treatment market. Investors view the initiation of this pivotal study as a positive indicator of the company's clinical pipeline progression.